drugset / Trial / NCT00843531
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Phase 2
Terminated
17 enrolled
University of California, San Francisco
Genentech, Inc. · collabNovartis Pharmaceuticals · collabThe V Foundation for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
Timeline
- Start
- 2009-06-25
- Primary completion
- 2013-07-16
- Completion
- 2016-08-20
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |